| Literature DB >> 28116167 |
J Campbell1, D Langdon2, M Cercignani1, W Rashid3.
Abstract
Aim. To explore the efficacy of home-based, computerised, cognitive rehabilitation in patients with multiple sclerosis using neuropsychological assessment and advanced structural and functional magnetic resonance imaging (fMRI). Methods. 38 patients with MS and cognitive impairment on the Brief International Cognitive Assessment for MS (BICAMS) were enrolled. Patients were randomised to undergo 45 minutes of computerised cognitive rehabilitation using RehaCom software (n = 19) three times weekly for six weeks or to a control condition (n = 19). Neuropsychological and MRI data were obtained at baseline (time 1), following the 6-week intervention (time 2), and after a further twelve weeks (time 3). Cortical activations were explored using fMRI and microstructural changes were explored using quantitative magnetisation transfer (QMT) imaging. Results. The treatment group showed a greater improvement in SDMT gain scores between baseline and time 2 compared to the control group (p = 0.005). The treatment group exhibited increased activation in the bilateral prefrontal cortex and right temporoparietal regions relative to control group at time 3 (p < 0.05FWE corrected). No significant changes were observed on QMT. Conclusion. This study supports the hypothesis that home-based, computerised, cognitive rehabilitation may be effective in improving cognitive performance in patients with MS. Clinical trials registration is ISRCTN54901925.Entities:
Mesh:
Year: 2016 PMID: 28116167 PMCID: PMC5223046 DOI: 10.1155/2016/4292585
Source DB: PubMed Journal: Neural Plast ISSN: 1687-5443 Impact factor: 3.599
Baseline demographic characteristics and cognitive performance.
| Treatment group ( | Control group ( | Mean difference (95% CI) |
| |
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | |||
| Age (years) | 46.21 (6.59) | 48.53 (9.63) | −2.31 (−7.75 to 3.12) | 0.588 |
| Disease duration (years) | 10.53 (6.13) | 12.68 (9.87) | −2.16 (−7.56 to 3.25) | 0.424 |
| EDSS | 4.42 (1.75) | 4.45 (1.77) | −0.26 (−1.18 to 1.13) | 0.964 |
| Education (years) | 14.05 (2.76) | 13.63 (2.89) | 0.42 (−1.43 to 2.28) | 0.649 |
| SDMT | 43.39 (7.39) | 38.21 (11.39) | 5.18 (−1.27 to 11.63) | 0.112 |
| CLVT | 45.32 (9.56) | 43.89 (9.73) | 1.42 (−4.93 to 7.77) | 0.653 |
| BVMT | 20.63 (5.77) | 18.05 (7.37) | 2.58 (−1.77 to 6.93) | 0.237 |
|
| ||||
|
|
| Odds ratio (95% CI) |
| |
|
| ||||
| Gender (female) | 13 (68.4) | 14 (73.6) | 0.74 (0.19 to 3.15) | 0.721 |
| Unemployed | 13 (68.4) | 11 (57.9) | 1.58 (0.42 to 5.95) | 0.501 |
| Disease subtype | ||||
| Relapsing-remitting | 14 (73.6) | 13 (68.4) | 1.29 (0.32 to 5.28) | 0.721 |
| Secondary-progressive | 5 (26.3) | 6 (31.6) | ||
| On treatment at enrolment | 12 (63.2) | 8 (42.1) | 2.38 (0.64 to 8.68) | 0.194 |
| Interferon | 5 | 2 | ||
| Fingolimod | 5 | 1 | ||
| Natalizumab | 2 | 4 | ||
| Teriflunomide | 0 | 1 | ||
∗ Includes Interferon (IF)-1b SC, IF-1A IM and IF-1A SC.
BICAMS outcomes in treatment versus control groups.
| Treatment ( | Control ( | Mean difference | 95% CI |
| |
| Mean (SD) | Mean (SD) | ||||
|
| |||||
|
| |||||
| SDMT gain | 3.94 (5.08) | −0.63 (3.30) | 4.56 | 1.47 to 7.66 | 0.005 |
| CVLT gain | 6.67 (7.56) | 4.06 (10.10) | 2.71 | −3.45 to 8.87 | 0.377 |
| BVMT gain | 4.65 (5.18) | 1.94 (4.17) | 2.70 | −0.52 to 5.93 | 0.098 |
|
| |||||
| Treatment ( | Control ( | Mean difference | 95% CI |
| |
| Mean (SD) | Mean (SD) | ||||
|
| |||||
|
| |||||
| SDMT gain | 3.35 (4.17) | 4.57 (7.21) | −1.28 | −5.45 to 3.01 | 0.582 |
| CVLT gain | 6.94 (7.01) | 7.50 (8.83) | −0.56 | −6.38 to 5.26 | 0.849 |
| BVMT gain | 7.29 (5.07) | 4.14 (5.32) | 3.15 | −0.68 to 6.98 | 0.105 |
SDMT: Symbol Digits Modalities Test; CVLT: California Verbal Learning Test; BVMT: Brief Visuospatial Memory Test.
Figure 1Improvement in SDMT slope immediately after intervention.
Figure 2Increased activations in treatment group relative to controls at follow-up. (a) Increased activation in treatment group in right parietal region (white arrow, p < 0.012FWE corrected) and left prefrontal region (dashed arrow, p < 0.001FWE corrected). (b) Bilateral frontal gyrus activation in treatment group relative to controls. Left MFG activation (arrow) significant at p ≤ 0.042FWE corrected at cluster level (k = 152).